Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.
PNNL is honoring its postdoctoral researchers as part of the fourteenth annual National Postdoc Appreciation Week with seven profiles of postdocs from around the Laboratory.
PNNL has named Biomedical Scientist Tom Metz, an expert on metabolomics and multi-omics within the Biological Sciences Division, a 2023 Laboratory Fellow.
PNNL’s wide-ranging report maps the current nanobiotechnology landscape, flags potential concerns, and details the need for an organizing body to coordinate currently disparate disciplines.
Small teams in the Biological Sciences Division at PNNL and at EMSL—the Environmental and Molecular Sciences Laboratory, an Office of Science user facility at PNNL—are pros at preparation.
COVID-19 infections at PNNL early in the pandemic were caused by a wide variety of viral sequences, according to a new analysis by Laboratory researchers.
PNNL chemist Christopher Anderton recently named president-elect of the Imaging Mass Spectrometry Society (IMSS). In this new position, he will help lead the merge of IMSS with a European-based society, currently underway.
Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.
Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.